Skip to content

NKGen Biotech, Inc.: 10-Q filed 2023-08-14

What NKGen Biotech, Inc. reported in its quarterly report filed 2023-08-14 (fiscal Q2 2023): 28 published measures, 82 facts as tagged in accession 0001410578-23-001926.

This filing

Form
10-Q (quarterly report)
Filed
2023-08-14
Fiscal period
fiscal Q2 2023
Accession
0001410578-23-001926 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NKGen Biotech, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-06-3063,605,533USD
At 2022-12-31174,366,108USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-06-309,348,398USD
At 2022-12-315,372,812USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-06-30-8,539,149USD
At 2023-03-31-5,299,272USD
At 2022-12-31-4,170,826USD
At 2022-06-30-4,210,526USD
At 2022-03-31-8,891,311USD
At 2021-12-31-10,894,701USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-06-3041,459USD
At 2022-12-31635,155USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-1,831,048USD91
2023-01-01 to 2023-06-30-1,452,171USD181
2023-01-01 to 2023-03-31378,877USD90
2022-04-01 to 2022-06-30956,139USD91
2022-01-01 to 2022-06-302,959,529USD181
2022-01-01 to 2022-03-312,003,390USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-1,061,645USD181
2022-01-01 to 2022-06-30-462,449USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-112,879,747USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-06-30113,347,696USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-06-30-8,539,578USD
At 2022-12-31-4,171,255USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-04-01 to 2023-06-3016,825,897shares91
2023-01-01 to 2023-06-3019,126,107shares181
2022-04-01 to 2022-06-3021,451,875shares91
2022-01-01 to 2022-06-3021,451,875shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-04-01 to 2023-06-3016,825,897shares91
2023-01-01 to 2023-06-3019,126,107shares181
2022-04-01 to 2022-06-3021,451,875shares91
2022-01-01 to 2022-06-3021,451,875shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-0.11USD/shares91
2023-01-01 to 2023-06-30-0.08USD/shares181
2022-04-01 to 2022-06-300.04USD/shares91
2022-01-01 to 2022-06-300.14USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-0.11USD/shares91
2023-01-01 to 2023-06-30-0.08USD/shares181
2022-04-01 to 2022-06-300.04USD/shares91
2022-01-01 to 2022-06-300.14USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2023-04-01 to 2023-06-30286,778USD91
2023-01-01 to 2023-06-30690,772USD181
2022-04-01 to 2022-06-30-15,402USD91
2022-01-01 to 2022-06-30-15,402USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-2,676,577USD91
2023-01-01 to 2023-06-30-3,631,419USD181
2022-04-01 to 2022-06-30-968,952USD91
2022-01-01 to 2022-06-30-1,700,860USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-06-3075,638USD
At 2022-12-31877,907USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-06-306,301,804USD
At 2022-12-312,845,588USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2023-06-30163,344USD
At 2022-12-31177,157USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2023-01-01 to 2023-06-30113,296,457USD181

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2023-04-01 to 2023-06-3045,000USD91
2023-01-01 to 2023-06-3090,000USD181
2022-04-01 to 2022-06-3045,000USD91
2022-01-01 to 2022-06-3090,000USD181

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-06-3041,459USD
At 2022-12-31635,155USD
At 2022-06-301,260,057USD
At 2021-12-311,722,506USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2023-06-305,050,540USD
At 2022-12-312,444,352USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-1,544,270USD91
2023-01-01 to 2023-06-30-761,399USD181
2022-04-01 to 2022-06-30940,737USD91
2022-01-01 to 2022-06-302,944,127USD181

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-1,452,171USD181
2022-01-01 to 2022-06-302,959,529USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-302,581,577USD91
2023-01-01 to 2023-06-303,441,419USD181
2022-04-01 to 2022-06-30874,637USD91
2022-01-01 to 2022-06-301,512,778USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-04-01 to 2023-06-301,132,307USD91
2023-01-01 to 2023-06-302,870,020USD181
2022-04-01 to 2022-06-301,909,689USD91
2022-01-01 to 2022-06-304,644,987USD181

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2023-01-01 to 2023-06-30300,000USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-13,813USD181
2022-01-01 to 2022-06-3079,438USD181

Inspect the source

Entity
NKGen Biotech, Inc. / CIK 0001845459
Captured
2026-09-21T17:32:02.047Z
SEC response SHA-256
8544e6c4131b39516897f64f9c1434fcc316a28920c7035efe74b5652ec44a1a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001845459.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))